ROX (Respiratory rate-OXygenation) index to predict early response to high-flow nasal cannula therapy in infants with viral bronchiolitis
Christophe Milesi1, Julien Baleine1, Erika Nogue2, Lionel Moulis2 MD; Robin Pouyau3; Arthur Gavotto1; David Brosssier4; Guillaume Mortamet5; Gilles Cambonie1, MD, PhD; for the GFRUP Respiratory Study Group*.
Affiliations: 1Pediatric Intensive Care Unit, Arnaud de Villeneuve University Hospital, Montpellier, France;2Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France;3Pediatric Intensive Care Unit, Woman-Mother-Child University Hospital, Lyon, France; 4 Pediatric Intensive Care Unit, University Hospital Caen-Normandy, France5Pediatric Intensive Care Unit, Grenoble University Hospital, La Tronche, France;
*The members of the GFRUP Respiratory Study Group are listed in the acknowledgments.
Correspondence: Christophe Milesi, MD, Department of Neonatal Medicine and Pediatric Intensive Care, Arnaud de Villeneuve University Hospital, 371 Avenue Doyen G Giraud, 34295 Montpellier Cedex 5, France.
Tel +33(0)467 336 609, Fax: +33(0)467 336 228, E-mail:c-milesi@chu-montpellier.fr
Key words: bronchiolitis, high-flow nasal cannula, infant, failure, risk prediction.
Word counts: text: 1758; Abstract: 320; Tables: 2; Figures: 1
Conflict of interest statement: The authors have no financial relationships and no potential conflicts of interest relevant to this article to disclose.